Overcoming Resistance in Malignant Brain Cancer
Glioblastoma
Glioblastoma (grade IV astrocytoma) is an aggressive primary brain tumor that is extremely difficult to treat. There is an unmet medical need for treatment as the current prognosis is only 8.7% of patients surviving two years.
The Discovery of CTO
While working as a patent attorney, Dr. Karmali had a client with a promising therapeutic for multiple cancerous indications. The client was interested in evaluating the therapy for prostate cancer.
Clinical Results of CTO
Phase I studies of CTO in Forty-four advanced cancer patients demonstrated that: CTO is orally bioavailable, safe, well tolerated and produces disease stabilization in a broad range of heavily treated refractory solid cancers.

Press Releases

Articles

Abstracts